Literature DB >> 2186980

Inhibition of nocturnal acidity is important but not essential for duodenal ulcer healing.

G Bianchi Porro1, F Parente, O Sangaletti.   

Abstract

We have determined the relative importance of day and night time gastric acid inhibition for duodenal ulcer healing by comparing the anti-ulcer efficacy of a single morning with that of a single bedtime dose of ranitidine. One hundred and thirty patients with active duodenal ulcer were randomly assigned to a double-blind therapy with ranitidine 300 mg at 8 am or the same dose at 10 pm for up to eight weeks. The antisecretory effects of these regimens were also assessed by 24 h intragastric pH monitoring in 18 of these patients. At four weeks ulcers had healed in 41/61 (67%) of patients taking the morning dose and in 47/63 (75%) of those receiving the nocturnal dose (95% CI for the difference -0.09 +0.25; p ns). At eight weeks, the corresponding healing rates were 82% and 85.5%, respectively (95% CI for the difference -0.11 +0.17; p ns). Both treatments were significantly superior to placebo in raising 24 h intragastric pH, although the effects of the morning dose were of shorter duration than those of the nocturnal dose. These findings suggest that suppression of nocturnal acidity is important but not essential to promote healing of duodenal ulcers; a prolonged period of acid inhibition during the day (as obtained with a single large morning dose of H2-blockers) may be equally effective.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186980      PMCID: PMC1378411          DOI: 10.1136/gut.31.4.397

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Vagotomy for Gastroduodenal Ulcer.

Authors:  L R Dragstedt
Journal:  Ann Surg       Date:  1945-12       Impact factor: 12.969

2.  Healing of duodenal ulcer with an antacid regimen.

Authors:  W L Peterson; R A Sturdevant; H D Frankl; C T Richardson; J I Isenberg; J D Elashoff; J Q Sones; R A Gross; R W McCallum; J S Fordtran
Journal:  N Engl J Med       Date:  1977-08-18       Impact factor: 91.245

3.  A controlled study comparing cimetidine treatment to an intensive antacid regimen in the therapy of uncomplicated duodenal ulcer.

Authors:  G Fedeli; M Anti; G L Rapaccini; I De Vitis; A Butti; I M Civello
Journal:  Dig Dis Sci       Date:  1979-10       Impact factor: 3.199

4.  Oxmetidine: clinical pharmacological studies with a new H2-receptor antagonist.

Authors:  J G Mills; P L Brunet; R Griffiths; R H Hunt; D Vincent; G J Milton-Thompson; W L Burland
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

5.  Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.

Authors:  F I Lee; P I Reed; J P Crowe; R L McIsaac; J R Wood
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

6.  Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacological study.

Authors:  M Deakin; H P Glenny; J K Ramage; J G Mills; W L Burland; J G Williams
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

7.  Early evening ranitidine administration promotes faster duodenal ulcer healing.

Authors:  H Merki; L Witzel; W Hüttemann; A Ansari; M Panijel; K Harre; J Heim; E Wolbergs; H J Neumann; J Röhmel
Journal:  Am J Gastroenterol       Date:  1988-04       Impact factor: 10.864

8.  Gastric secretion and emptying after ordinary meals in duodenal ulcer.

Authors:  J R Malagelada; G F Longstreth; T B Deering; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1977-11       Impact factor: 22.682

9.  A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.

Authors:  N Gitlin; A J McCullough; J L Smith; G Mantell; R Berman
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

10.  The natural history of peptic ulcer disease: the influence of H2-antagonist treatment.

Authors:  G Bianchi Porro; M Petrillo
Journal:  Scand J Gastroenterol Suppl       Date:  1986
View more
  5 in total

1.  Mealtime versus nighttime acid inhibition. A clinical pharmacological study with ranitidine.

Authors:  V Savarino; G S Mela; P Zentilin; S Vigneri; P Cutela; R Mele; F Di Mario
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

2.  A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers.

Authors:  M Okada; M Arita; M Iida; T Yao; T Sakurai; K Hoshiko; K Maeda; Y Okada; K Sakamoto
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 3.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 4.  Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.

Authors:  M Deakin; J G Williams
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 5.  The H2-receptor antagonist era in duodenal ulcer disease.

Authors:  I N Marks
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.